Efter at CHMP har afgivet sin udtalelse, er Europa- Kommissionen sædvanligvis ca. to måneder om at udstede tilladelsen.
Based on the review of the data and the company’ s response to the CHMP list of questions, at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Lacosamide Pain UCB Pharma could not have been approved for the treatment of diabetic neuropathic pain in adults.